Newstral
Article
lasvegassun.com on 2019-10-23 01:03
Biogen reanalyzes studies, presses ahead on Alzheimer's drug
Related news
- Biogen cutting cost of Alzheimer's drugArkansas Online
- MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min readmarketwatch.com
- Biogen shares soar as FDA reviewers support Alzheimer's drugSydney Morning Herald
- WAlzheimer's drug from Biogen, partner receives FDA approvalwraltechwire.com
- MBiogen talks up approval plans for controversial Alzheimer's drug as it nears FDA decisionmarketwatch.com
- Company says it will seek approval of Alzheimer’s drugartesianews.com
- Biogen cuts the price tag on its Alzheimer's drug in half - Mon, 20 Dec 2021 PSTapnews.com
- Change at the top for Biogen after Alzheimer's drug flops - Tue, 03 May 2022 PSTapnews.com
- BBiogen Stock Is Tumbling Because Its Alzheimer's Drug Rollout Isn't Going So Well2 min readbarrons.com
- Alzheimer's drug draws mixed reviewsnwaonline.com
- BFDA Will Weigh Full Approval for Alzheimer's Drug. Why It Matters for Biogen Stock. 3 min readbarrons.com
- MOne Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments 2 min readmarketwatch.com
- Studies in healthy older people aim to prevent Alzheimer'sKHQ Local News
- Biogen trial drug shows promise in fight against Alzheimer'sThe Japan Times
- Biogen Drug Could Inspire New Hope For Alzheimer'sForbes
- Company says it will seek approval of Alzheimer’s drug - Tue, 22 Oct 2019 PSTThe Spokesman-Review
- FDA calls for investigation of Biogen Alzheimer's drug approvalbizjournals.com
- Biogen to cease production of controversial Alzheimer's drugPOLITICO